Systematic Optimization of PD-L1 and CLDN18.2 CAR-T Designs for Gastric Cancer

A research article detailing the stepwise optimization of chimeric antigen receptor (CAR) T-cell designs targeting PD-L1 and Claudin18.2 for gastric cancer therapy. The study, authored by Xiang Zhang and published on figshare in 2026, includes in vitro and in vivo evaluations of single-target and bicistronic dual-target CAR-T cells. Results show a double-CD3ζ architecture achieved 63.23% tumor growth inhibition in a xenograft model.

Use Cases

• Benchmarking CAR-T cell design performance based on cytotoxicity and expansion data described in the study
• Analyzing the impact of different costimulatory domains (CD28 vs. 4-1BB) on T-cell function as discussed in the methods
• Investigating the relationship between CAR signaling architecture and immune activation/exhaustion markers from the RNA sequencing results
• Comparing the antitumor efficacy of single-target versus dual-target CAR-T cells using the in vivo xenograft model results

Strengths

• Includes specific quantitative results, such as a 63.23% tumor growth inhibition rate for the double-CD3ζ design
• Describes a systematic, stepwise experimental methodology for CAR design optimization
• Provides comparative analysis of multiple CAR architectures (monospecific and bicistronic) and signaling configurations

Limitations

• The dataset is a 175.4 KB PDF document; the underlying raw experimental data (e.g., sequencing reads, flow cytometry files) is not directly provided
• Row count and column-level documentation for any underlying tabular data are unknown
• Data may reflect the specific experimental conditions and cell lines (e.g., NUGC4-Luc) used in the study

Provenance

Source

figshare, authored by Xiang Zhang

Collection Method

Experimental research involving CAR-T cell engineering, in vitro assays, and in vivo xenograft models.

Freshness

Last updated 2026-06-02 08:07:24